A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Public ClinicalTrials.gov record NCT07488676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion. In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C. In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people with gastric cancer or GEJ cancer. All people in this part of the study will receive an infusion of the higher dose of ASP546C. People will visit the clinic on certain days to receive ASP546C and have health checks. The number of visits and checks done during the study will depend on the health of each person and whether they are still receiving infusions of ASP546C.
Study identification
- NCT ID
- NCT07488676
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2026 (Actual)
- Primary completion
- Jul 31, 2029 (Estimated)
- Completion
- Jul 31, 2029 (Estimated)
- Last update posted
- Sep 22, 2026
2026 – 2029
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UAB Medicine - UAB Hospital | Birmingham | Alabama | 35249 | Recruiting |
| START Los Angeles | Los Angeles | California | 90025 | Recruiting |
| Miami Cancer Institute | Miami | Florida | 33176 | Recruiting |
| Winship Cancer Institute at Emory University | Atlanta | Georgia | 30322 | Recruiting |
| Indiana University (IU) Health - Multi-D Oncology Clinic | Indianapolis | Indiana | 46202 | Recruiting |
| Barbara Ann Karmanos Cancer Center | Detroit | Michigan | 48201 | Recruiting |
| START Midwest | Grand Rapids | Michigan | 49546 | Recruiting |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | Recruiting |
| START New York | Lake Success | New York | 10042 | Recruiting |
| Duke Cancer Center Durham | Durham | North Carolina | 27710 | Recruiting |
| Next Oncology - Austin | Austin | Texas | 78758 | Recruiting |
| Next Oncology - Houston | Houston | Texas | 77054 | Recruiting |
| Next Oncology - Dallas | Irving | Texas | 75039 | Recruiting |
| START San Antonio (STSA) | San Antonio | Texas | 78229 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
| Inova Schar Cancer Institute Clinical Trials | Fairfax | Virginia | 22031 | Recruiting |
| UW Health Carbone Cancer Center | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07488676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2026 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07488676 live on ClinicalTrials.gov.